Varun Modi, MD
Hematology & Oncology · Middletown, NYNPI 1295126670
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.6% of the total across 92 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in NY, where the typical reported total is $1,337.
Across 92 payments — averaging $19.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$359
- Tempus AI, Inc$171
- Array Biopharma Inc$151
- Novartis$147
- Johnson & Johnson$127
- AstraZeneca$108
- plus $741 from 19 others
What the payments were for
- Food & beverage$1,65392%
- Education$1518%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 23 | $359 |
| Tempus AI, Inc | 3 | $171 |
| Array Biopharma Inc | 11 | $151 |
| Novartis | 7 | $147 |
| Johnson & Johnson | 2 | $127 |
| AstraZeneca(2 entities) | 6 | $108 |
| Amgen | 6 | $91 |
| E.r. Squibb & Sons, L.L.C. | 5 | $78 |
| Merck | 5 | $77 |
| Ipsen Biopharmaceuticals, Inc | 2 | $71 |
| Gilead(2 entities) | 3 | $68 |
| Bristol Myers Squibb | 3 | $45 |
| Sanofi | 1 | $41 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $37 |
| Astellas Pharma US Inc | 2 | $37 |
| Genentech USA, Inc. | 2 | $27 |
| Janssen Scientific Affairs, LLC | 1 | $23 |
| Eisai Inc. | 1 | $22 |
| Blue Earth Diagnostics | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Sobi, Inc | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Menarini Silicon Biosystems, Inc. | 1 | $16 |
| Incyte Corporation | 1 | $15 |
| BTG International Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XT CDX$123
How this compares
$1,804 in reported general payments places this provider in the 50th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 41 | $570,688 |
| JakafiRuxolitinib Phosphate | 21 | $264,334 |
| Neulasta OnproPegfilgrastim | 35 | $259,149 |
| NeulastaPegfilgrastim | 25 | $236,049 |
| ImfinziDurvalumab | 17 | $211,672 |
| BrukinsaZanubrutinib | 13 | $195,485 |
| TagrissoOsimertinib Mesylate | 12 | $192,025 |
| Lenalidomide | 13 | $168,581 |
| JevtanaCabazitaxel | 11 | $136,887 |
| Lupron DepotLeuprolide Acetate | 18 | $100,871 |
| EliquisApixaban | 100 | $71,654 |
| AkynzeoFosnetupitant/Palonosetron | 69 | $71,347 |
| AranespDarbepoetin Alfa In Polysorbat | 14 | $28,493 |
| XareltoRivaroxaban | 19 | $19,843 |
| Gemcitabine Hcl | 15 | $3,979 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $37 | $570,68841 claims |
| AstraZenecaImfinzi, Tagrisso | $108 | $403,69729 claims |
| AmgenNeulasta, Aranesp | $91 | $264,54239 claims |
| Incyte CorporationJakafi | $15 | $264,33421 claims |
| SanofiJevtana | $41 | $136,88711 claims |
| PfizerEliquis | $359 | $71,654100 claims |
| Johnson & JohnsonXarelto | $127 | $19,84319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 967 hematology & oncology providers in New York.
Other hematology & oncology in Middletown
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Francis ArenaLake Success$1M
- Sanjeev JainEast Patchogue$971K
- Ross LevineNew York$968K
- Perry CookBrooklyn$803K
- Mihir RavalAlbany$767K
- Joshua SabariNew York$761K
- Gail RobozNew York$738K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.